{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:15:31Z","timestamp":1792451731400,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, leads to prominent glucosylceramide accumulation in lysosomes of tissue macrophages (Gaucher cells). Here we show glucosylsphingosine, the deacylated form of glucosylceramide, to be markedly increased in plasma of symptomatic nonneuronopathic (type 1) Gaucher patients (n = 64, median = 230.7nM, range 15.6-1035.2nM; normal (n = 28): median 1.3nM, range 0.8-2.7nM). The method developed for mass spectrometric quantification of plasma glucosylsphingosine is sensitive and robust. Plasma glucosylsphingosine levels correlate with established plasma markers of Gaucher cells, chitotriosidase (\u03c1 = 0.66) and CCL18 (\u03c1 = 0.40). Treatment of Gaucher disease patients by supplementing macrophages with mannose-receptor targeted recombinant glucocerebrosidase results in glucosylsphingosine reduction, similar to protein markers of Gaucher cells. Since macrophages prominently accumulate the lysoglycosphingolipid on glucocerebrosidase inactivation, Gaucher cells seem a major source of the elevated plasma glucosylsphingosine. Our findings show that plasma glucosylsphingosine can qualify as a biomarker for type 1 Gaucher disease, but that further investigations are warranted regarding its relationship with clinical manifestations of Gaucher disease.<\/jats:p>","DOI":"10.1182\/blood-2011-05-352971","type":"journal-article","created":{"date-parts":[[2011,8,26]],"date-time":"2011-08-26T03:07:34Z","timestamp":1314328054000},"page":"e118-e127","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":266,"title":["Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response"],"prefix":"10.1182","volume":"118","author":[{"given":"Nick","family":"Dekker","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"van Dussen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E. M.","family":"Hollak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Overkleeft","sequence":"additional","affiliation":[{"name":"Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Scheij","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ghauharali","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle J.","family":"van Breemen","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Ferraz","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna E. M.","family":"Groener","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maas","sequence":"additional","affiliation":[{"name":"Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits A.","family":"Wijburg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Speijer","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szymanska","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Children's Memorial Health Institute, Warsaw, Poland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K.","family":"Mistry","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology & Hepatology, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf G.","family":"Boot","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111808090340600_B1","first-page":"3635","article-title":"Gaucher disease.","volume-title":"The Metabolic and Molecular Bases of Inherited Diseases","author":"Beutler","year":"2001"},{"issue":"21","key":"2019111808090340600_B2","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease.","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111808090340600_B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nrd3311","article-title":"Velaglucerase alfa.","volume":"9","author":"Aerts","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"9214","key":"2019111808090340600_B4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"2019111808090340600_B5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1010335505357","article-title":"Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.","volume":"24","author":"Platt","year":"2001","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"2019111808090340600_B6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis.","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111808090340600_B7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis"},{"issue":"2\u20133","key":"2019111808090340600_B8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders.","volume":"29","author":"Aerts","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"457","key":"2019111808090340600_B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1651-2227.2007.00641.x","article-title":"Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease.","volume":"97","author":"Aerts","year":"2008","journal-title":"Acta Paediatr Suppl"},{"issue":"3","key":"2019111808090340600_B10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.","volume":"93","author":"Hollak","year":"1994","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111808090340600_B11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111808090340600_B12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/08035250500423804","article-title":"Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.","volume":"95","author":"Erikson","year":"2006","journal-title":"Acta Paediatr"},{"issue":"3","key":"2019111808090340600_B13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.bcmd.2007.10.004","article-title":"Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention.","volume":"40","author":"Meikle","year":"2008","journal-title":"Blood Cells Mol Dis"},{"issue":"1\u20132","key":"2019111808090340600_B14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbalip.2007.11.004","article-title":"Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention.","volume":"1781","author":"Groener","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20132","key":"2019111808090340600_B15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","article-title":"Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.","volume":"389","author":"Ghauharali-van der Vlugt","year":"2008","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2019111808090340600_B16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0006-291X(73)90916-9","article-title":"Deficiency of glucosylsphingosine: beta-glucosidase in Gaucher disease.","volume":"54","author":"Raghavan","year":"1973","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2019111808090340600_B17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease,","volume":"39","author":"Nilsson","year":"1982","journal-title":"J Neurochem"},{"issue":"4","key":"2019111808090340600_B18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2019111808090340600_B19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.nbd.2003.08.016","article-title":"Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3.","volume":"14","author":"Schueler","year":"2003","journal-title":"Neurobiol Dis"},{"issue":"45","key":"2019111808090340600_B20","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage.","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111808090340600_B21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/bj20030613","article-title":"Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms.","volume":"375","author":"Lloyd-Evans","year":"2003","journal-title":"Biochem J"},{"issue":"6","key":"2019111808090340600_B22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/hmg\/ddp580","article-title":"Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.","volume":"19","author":"Sun","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2019111808090340600_B23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal disorders: from storage to cellular damage.","volume":"1793","author":"Ballabio","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2019111808090340600_B24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-2275(20)39839-4","article-title":"Krabbe disease: a galactosylsphingosine (psychosine) lipidosis.","volume":"21","author":"Svennerholm","year":"1980","journal-title":"J Lipid Res"},{"issue":"8","key":"2019111808090340600_B25","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease.","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2019111808090340600_B26","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/intimm\/dxh328","article-title":"Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity.","volume":"17","author":"van Eijk","year":"2005","journal-title":"Int Immunol"},{"issue":"12","key":"2019111808090340600_B27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nchembio.466","article-title":"Ultrasensitive in situ visualization of active glucocerebrosidase molecules.","volume":"6","author":"Witte","year":"2010","journal-title":"Nat Chem Biol"},{"issue":"2","key":"2019111808090340600_B28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2007.02.042","article-title":"Monitoring of Gaucher patients with a novel chitotriosidase assay.","volume":"381","author":"Schoonhoven","year":"2007","journal-title":"Clin Chim Acta"},{"issue":"7","key":"2019111808090340600_B29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1 beta levels in type 1 Gaucher disease.","volume":"1772","author":"van Breemen","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"2019111808090340600_B30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages.","volume":"122","author":"Boven","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"19","key":"2019111808090340600_B31","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1111\/j.1742-4658.2009.07259.x","article-title":"Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates.","volume":"276","author":"Bussink","year":"2009","journal-title":"FEBS J"},{"issue":"40","key":"2019111808090340600_B32","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene. Nature of inherited enzyme deficiency.","volume":"273","author":"Boot","year":"1998","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111808090340600_B33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcmd.2010.10.010","article-title":"Potential biomarkers of osteonecrosis in Gaucher disease.","volume":"46","author":"Pavlova","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"2019111808090340600_B34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10545-009-1064-5","article-title":"Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.","volume":"32","author":"van Breemen","year":"2009","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"2019111808090340600_B35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-008-0873-2","article-title":"Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.","volume":"31","author":"Cox-Brinkman","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2019111808090340600_B36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter.","volume":"179","author":"Maas","year":"2002","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"2019111808090340600_B37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/pd.2584","article-title":"Sixteen years of prenatal consultations for the N370S\/N370S Gaucher disease genotype: what have we learned?","volume":"30","author":"Eitan","year":"2010","journal-title":"Prenat Diagn"},{"issue":"6","key":"2019111808090340600_B38","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1016\/S0021-9258(19)67845-2","article-title":"Characterization of human glucocerebrosidase from different mutant alleles.","volume":"266","author":"Ohashi","year":"1991","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111808090340600_B39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant.","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2019111808090340600_B40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0950-3536(97)80034-0","article-title":"Plasma and metabolic abnormalities in Gaucher's disease.","volume":"10","author":"Aerts","year":"1997","journal-title":"Baillieres Clin Haematol"},{"issue":"2","key":"2019111808090340600_B41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bcmd.2005.05.005","article-title":"Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.","volume":"35","author":"Deegan","year":"2005","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"2019111808090340600_B42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF02533018","article-title":"Enzymatic synthesis of glucosylsphingosine by rat brain microsomes.","volume":"7","author":"Curtino","year":"1972","journal-title":"Lipids"},{"issue":"2","key":"2019111808090340600_B43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1432-1033.1985.tb08655.x","article-title":"Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase.","volume":"146","author":"Vaccaro","year":"1985","journal-title":"Eur J Biochem"},{"issue":"1","key":"2019111808090340600_B44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bcmd.2010.07.009","article-title":"The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation.","volume":"46","author":"Dekker","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2019111808090340600_B45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/oxfordjournals.jbchem.a124584","article-title":"The synthetic pathway for glucosylsphingosine in cultured fibroblasts.","volume":"116","author":"Yamaguchi","year":"1994","journal-title":"J Biochem"},{"issue":"6","key":"2019111808090340600_B46","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1399-0004.2007.00899.x","article-title":"Non-neuronopathic Gaucher disease due to saposin C deficiency.","volume":"72","author":"Tylki-Szymanska","year":"2007","journal-title":"Clin Genet"},{"issue":"6","key":"2019111808090340600_B47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0009-9120(87)90010-5","article-title":"Effect of a heat-stable factor in human placenta on glucosylceramidase, glucosylsphingosine glucosyl hydrolase, and acid beta-glucosidase activities.","volume":"20","author":"Vaccaro","year":"1987","journal-title":"Clin Biochem"},{"issue":"1","key":"2019111808090340600_B48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0005-2760(76)90055-2","article-title":"Comparative studies on chemical, hemolytic and diffusion-in-gel precipitation properties of various lysosphingolipids.","volume":"424","author":"Taketomi","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"4890","key":"2019111808090340600_B49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.2643164","article-title":"Functions of sphingolipids and sphingolipid breakdown products in cellular regulation.","volume":"243","author":"Hannun","year":"1989","journal-title":"Science"},{"issue":"1","key":"2019111808090340600_B50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim Biophys Acta"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/16\/e118\/1342775\/zh80421100e118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/16\/e118\/1342775\/zh80421100e118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:05:17Z","timestamp":1638403517000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/16\/e118\/28851\/Elevated-plasma-glucosylsphingosine-in-Gaucher"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,20]]},"references-count":50,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2011,10,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-352971","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,20]]}}}